Cargando…
Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692278/ https://www.ncbi.nlm.nih.gov/pubmed/37889496 http://dx.doi.org/10.1182/bloodadvances.2023011694 |
| _version_ | 1785152908689408000 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10692278 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106922782023-12-03 Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785. Blood Adv Erratum The American Society of Hematology 2023-10-31 /pmc/articles/PMC10692278/ /pubmed/37889496 http://dx.doi.org/10.1182/bloodadvances.2023011694 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Erratum Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785. |
| title | Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785. |
| title_full | Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785. |
| title_fullStr | Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785. |
| title_full_unstemmed | Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785. |
| title_short | Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785. |
| title_sort | gill s, vides v, frey nv, et al. anti-cd19 car t cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. blood adv. 2022;6(21):5774-5785. |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692278/ https://www.ncbi.nlm.nih.gov/pubmed/37889496 http://dx.doi.org/10.1182/bloodadvances.2023011694 |